Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 220 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: .9 normal saline Clear all
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924
View directory record Official record
Conditions
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Interventions
AOC 1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes

NCT00585325
View directory record Official record
Conditions
Burn
Interventions
Instilled 1% Lidocaine, Placebo (0.9% Normal Saline)
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

NCT02860650
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Filo, MVA-BN-Filo, Ad26.ZEBOV, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery

NCT02689258
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578
View directory record Official record
Conditions
Bacterial Disease Carrier, Cystic Fibrosis
Interventions
Placebo, WRAIR-PAM-CF1
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 4 Interventional

Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries

NCT02980835
View directory record Official record
Conditions
Video-Assisted Thoracic Surgery, Video-Assisted Thoracoscopic Surgery
Interventions
Normal Saline, Ropivacaine, Epinephrine, Dexamethasone
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 10, 2026, 2:40 PM EDT
Withdrawn Phase 2 Interventional

Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant

NCT02115126
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
LMP2A-loaded conventional DC vaccine, DUK-CPG-001
Biological
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

NCT01221246
View directory record Official record
Conditions
Stroke
Interventions
GM602, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Pasadena, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

NCT03036488
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
47
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Adult - Chiron Study of Bird Flu Vaccine

NCT00280033
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 10, 2026, 2:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

NCT00835328
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 10, 2026, 2:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting Phase 2 Interventional

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

NCT06321536
View directory record Official record
Conditions
Multi-Drug Resistant Organism Colonization
Interventions
Allogeneic Microbiota in Glycerol (9%) (AMG)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia • Hinsdale, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Contact Lens Saline Solutions With Scleral GP Contact Lens Wearers Experiencing Fogging

NCT03525704
View directory record Official record
Conditions
Contact Lens Complication, Debris in Post Lens Tear Reservoir
Interventions
Saline Solution Enriched, Saline Rinse Solution
Device
Lead sponsor
Contamac Ltd
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
West Linn, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population

NCT06538584
View directory record Official record
Conditions
Enhanced Recovery After Surgery in a Pediatric Population
Interventions
Caffeine citrate 15mg/kg, 0.9% Sodium Citrate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
3 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

NCT02773979
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Chloroquine, PfSPZ (NF54) Challenge, Placebo
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 10, 2026, 2:40 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Ketamine Frequency Treatment for Major Depressive Disorder

NCT00646087
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Ketamine/Saline
Drug
Lead sponsor
Essentia Health
Other
Eligibility
30 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 10, 2026, 2:40 PM EDT
Enrolling by invitation No phase listed Observational

PET/MRI for Evaluation of Endometriosis

NCT06377553
View directory record Official record
Conditions
Endometriosis, Endometrioma
Interventions
Radiotracer Injection, Imaging, Rectal Ultrasound Gel Injection
Drug · Diagnostic Test · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
60 participants
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Results available

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

NCT00728936
View directory record Official record
Conditions
Hepatitis C
Interventions
IMO-2125, Saline placebo
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Aurora, Colorado • Marietta, Georgia • Novi, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

NCT05619536
View directory record Official record
Conditions
Healthy
Interventions
CD388 Injection, Saline placebo
Combination Product · Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

NCT00935883
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Eculizumab, Saline
Drug
Lead sponsor
Philip J. Rosenfeld, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 10, 2026, 2:40 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting Phase 4 Interventional

Volume Reduction for Open Fracture Irrigation

NCT07437339
View directory record Official record
Conditions
Open Fracture
Interventions
0.9% Sodium Chloride
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 10, 2026, 2:40 PM EDT